Payment overview · 2025
General Payments
$205.31
10 reported records · 6 companies
Healthcare provider profile · identity verified
Carol M Odegaard, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, GA · NPI 1700876554
Verified facts
What the public records show
CMS Open Payments records show Carol M Odegaard, M.D. received $205.31 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Wegovy.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.00 | 36.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.40 | 24.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.67 | 11.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.19 | 10.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.56 | 10.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.49 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $189.04 | 9 |
| Education | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.40 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.71 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.29 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 138 |
| Lisinopril | Lisinopril | 427 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 105 |
| Ezetimibe | Ezetimibe | 215 | 67 |
| Losartan Potassium | Losartan Potassium | 212 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 62 |
| Omeprazole | Omeprazole | 188 | 54 |
| Alprazolam | Alprazolam | 182 | 43 |
| Potassium Chloride | Potassium Chloride | 169 | 53 |
| Famotidine | Famotidine | 166 | 50 |
| Gabapentin | Gabapentin | 166 | 52 |
| Metformin Hcl | Metformin Hcl | 158 | 46 |
| Metformin Hcl Er | Metformin Hcl | 152 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 43 |
| Trazodone Hcl | Trazodone Hcl | 148 | 46 |
| Simvastatin | Simvastatin | 143 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 49 |
| Alendronate Sodium | Alendronate Sodium | 132 | 44 |
| Glimepiride | Glimepiride | 129 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 39 |
| Furosemide | Furosemide | 124 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 32 |
| Tramadol Hcl | Tramadol Hcl | 120 | 44 |
| Fenofibrate | Fenofibrate | 101 | 36 |
| Januvia | Sitagliptin Phosphate | 89 | 22 |
| Montelukast Sodium | Montelukast Sodium | 89 | 25 |
| Methylprednisolone | Methylprednisolone | 85 | 66 |
| Atenolol | Atenolol | 83 | 22 |
| Allopurinol | Allopurinol | 82 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 23 |
| Ozempic | Semaglutide | 70 | 23 |
| Eliquis | Apixaban | 69 | 16 |
| Sertraline Hcl | Sertraline Hcl | 69 | 22 |
| Ibuprofen | Ibuprofen | 64 | 23 |
| Cefuroxime | Cefuroxime Axetil | 61 | 54 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 14 |
| Spironolactone | Spironolactone | 53 | 14 |
| Bupropion Xl | Bupropion Hcl | 52 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 15 |
| Carvedilol | Carvedilol | 50 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 45 | 15 |
| Clonazepam | Clonazepam | 44 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 39 |
| Meloxicam | Meloxicam | 43 | 18 |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Temazepam | Temazepam | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 22 |
| Glipizide | Glipizide | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 23 |
| Lorazepam | Lorazepam | 36 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 24 |
| Diazepam | Diazepam | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 18 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 12 |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Finasteride | Finasteride | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $205.31 · 10 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, OTEZLA, Ozempic, REPATHA, Rybelsus, VYNDAMAX, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error